Life-threatening deaths and SAAs must be replaced in less than 7 calendar days. As a general rule, this boiler platform is not sufficient to cover all issues and a sentence should be added indicating that the parties will launch a formal and detailed written SDEA within 6 days of signing the contract. The “xx” depends on when patients are exposed to the product. A safety exchange mechanism must be put in place before a patient receives a drug. All this means that large amounts of data are collected and exchanged between companies. In the world of drug safety and pharmacovigilance, there are specific requirements for the exchange, database, analysis and communication of security data. The SDEAs vary depending on the role of the third part. If the third party only carries out sales activities, their exposure to security data may only require simple instructions on what to do if they run into problems. If the third party is more involved, a distributor, co-marketing companies, co-developer companies or licensees, the SDEA will be more detailed. If outsourced activity is pharmacovigilance, ADEDs need to be more detailed, as it is essential that all parties involved are aware of their security reporting responsibilities and processes. A security data exchange contract is a legal written contract that ensures that all drug safety data is recovered quickly and reliably from the market authorization holder so that they can meet their legal obligations. Contact information such as phone number, email ID for the communication of security-related details For a regular security update report (PSUR), the date that is the deadline for… Outsourcing pharmacovigilance and allocating drug safety and regulatory activities can significantly reduce costs and workload for each marketing authorization holder (MAH).
However, overall responsibility and monitoring of the pharmacovigilance system remains the responsibility of the MAH and the EU QPPV. In particular, it is the MAH`s responsibility to properly receive the process and expedite reports on adverse events and other safety reports if necessary. Although all pharmacovigilance activities are outsourced, overall responsibility lies with the MAH. The legal and regulatory responsibility for any failure of a pharmacovigilance provider to properly comply with pharmacovigilance legislation rests with the MAH, not with the company to which pharmacovigilance has been outsourced. In many companies, the legal department knows all the partners involved in the marketing of companies` products. In large companies that sell hundreds of drugs in more than a hundred countries, there can be tens of thousands of such contracts! This was certainly the case in one of the large companies where I worked for many years.